UK breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 9.0% during the forecast period. Increasing the incidence of breast cancer coupled with government initiatives are the major factors that contributing to the growth of the market. According to Cancer Research UK, incidence rates for breast cancer are projected to rise by 2% in the UK between 2014 and 2035, to 210 cases per 100,000 females by 2035.
Request a Free Sample of our Report on UK Breast Cancer Diagnostics and Therapeutics Market: https://www.omrglobal.com/request-sample/uk-breast-cancer-diagnostics-therapeutics-market
The awareness programs and research funding on breast cancer also enable the growth of the market. In 2015 the Public Health England (PHE) launched the ‘Be Clear on Cancer’ campaign for the purpose of women aged 70 and over to drive awareness of the risk of breast cancer. Cancer Research UK funded about $38 million for breast cancer research in 2017. This funding enabled to create a network of research at 90 institutions in more than 40 states in the UK.
UK breast cancer diagnosis and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/computed tomography, ultrasound, and others. The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others.
The companies which are contributing to the growth of UK breast cancer diagnostics and therapeutics market include, Agendia NV, AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Mylan NV, Merck & Co., Inc., Novartis International AG, F. Hoffmann-La Roche AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
A Full Report of UK Breast Cancer Diagnostics and Therapeutics Market is Available at https://www.omrglobal.com/industry-reports/uk-breast-cancer-diagnostics-therapeutics-market
UK Breast Cancer Diagnostics and Therapeutics Market
By Cancer Type
- Ductal Carcinoma In-Situ (DCIS)
- Invasive Ductal Carcinoma (IDC)
- Triple Negative Breast Cancer (TNBC)
- Inflammatory Breast Cancer
- Others (Invasive lobular carcinoma)
- 5.2.3. PET/CET
- Others (MRI)
- Hormone Therapy
- Targeted Therapy
- Others (Radiation Therapy, Surgery)
- AstraZeneca PLC
- Bayer AG
- GlaxoSmithKline PLC
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis International AG
- F. Hoffmann-La Roche AG
- Sanofi S.A.
- Siemens Healthcare GmbH
- Sun Pharmaceutical Industries Ltd.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/uk-breast-cancer-diagnostics-therapeutics-market
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit https://www.omrglobal.com/
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404